Skip to main content
IDWeek 2024 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
Live Streamed
On Demand
On Demand
Back

Ryan H. Rochat, MD, PhD, MS

Assistant Professor
Baylor College of Medicine
Houston, Texas, United States

My experience as an MD/PhD has been a variegated and unique one. My exposure to bioinformatics during my graduate training in Genetic Epidemiology and Big Data during my PhD training has shaped the way in which I approach medicine in the era of the Electronic Health Records (EHRs). I had my first foray into informatics during my Masters training when I developed a series of computer programs to collect, parse, and aggregate genetic data from queries of large publicly available databases to focus selection of Single Nucleotide Polymorphisms for genetic research. During my residency training I focused my efforts developing a series of computer programs that would parse the EHR and systematically re-write themselves to adapt to the varied input data to determine rates of medication side-effects. It is this background that has given me a unique perspective to medicine and nurtured my unconventional approach to data processing, informatics, and research. I have a special interest in bioinformatics and during my fellowship in pediatric infectious disease I used high-throughput informatics to understand the healthcare associated costs of congenital infections to better understand the progression of these diseases and their many sequelae throughout time. It is my belief that by normalizing the evaluation and management of children with congenital syphilis within a centralized clinic, not only will we be able to provide excellence in patient care, but also provide a useful resource to providers, the community, and local health departments. By integrating the evaluation and management of these children across the vast hospital system at Texas Children’s Hospital, I feel we will be exceptionally well equipped to understand the natural epidemiology of this congenital infection and prioritize treatment, and patient follow up, to ebb this current trend.

Disclosure(s): Merck Sharp & Dohme Corporation: Grant/Research Support (Terminated, December 31, 2023)

Presentation(s):